Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?

VJHemOnc

1 year
59 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolongation, among many others. Here, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains how these side effects are minimal and well tolerated in most patients. Dr Stein highlights how differentiation syndrome, characterized by symptoms such as unexplained fever, weight gain and peripheral edema, should be addressed immediately with high doses of steroids. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
14 Views
Cancer-News 1 month
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
300 Views
obr 5 months
The Recent Wave of Approval in AML
The Recent Wave of Approval in AML
Category: Acute Myelogenous Leukemia
138 Views
obr 5 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
16 Views
obr 5 months
Latest Data on Uproleselan with Chemotherapy
Latest Data on Uproleselan with Chemotherapy
Category: Acute Myelogenous Leukemia
100 Views
obr 5 months
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
Category: Acute Myelogenous Leukemia
115 Views
imedex 6 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
177 Views
imedex 6 months
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Category: Acute Myelogenous Leukemia
100 Views
Annual-Meeting 6 months
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Category: Acute Myelogenous Leukemia
107 Views
Annual-Meeting 6 months